Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has been trading with ups and downs since the past few days, after the company announced better-than-expected results and its plans to partner for its flagship drug Iclusig. One of the major takeaway during the earnings call is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s CEO Harvey Berger’s indication for potential partnership in Japan for Iclusig, as the formal announcement is expected to come soon. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.94% in last session and finished the day at $8.58. Traded volume was 8,713,042 million shares in the last session and the average volume of the stock remained 27.51 million shares. The beta of the stock remained 1.41. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Biopharmaceutical company Peregrine Pharmaceuticals (NASDAQ:PPHM), jumped a whopping 47.6% after disclosing that it would have three pre-clinical data presentations at the upcoming Keystone Symposia conferences. Peregrine Pharmaceuticals (NASDAQ:PPHM) rose 47.64 percent to $2.82 yesterday on volume of 36.76 million shares. The intra-day range of the stock was $1.98 to $2.88. Peregrine Pharmaceuticals (NASDAQ:PPHM) has a market capitalization of $452.12 million.

MannKind Corporation (NASDAQ:MNKD) presented at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley in Boston, Massachusetts on March 3, 2014. MannKind Corporation (NASDAQ:MNKD)’s stock on Mar 5, 2014 reported a decrease of -3.13% to the closing price of $5.89. Its fifty two weeks range is $2.65 -$8.70. The total market capitalization recorded $2.18 billion. The overall volume in the last trading session was 7,870,358 million shares. In its share capital, MannKind Corporation (NASDAQ:MNKD) has 337.28 million outstanding shares.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) on Mar. 3 announced that Safi R. Bahcall, Ph.D., has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective immediately, and has been replaced by a newly formed Executive Committee of the Board. On Wednesday, shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) dropped -13.49% to close the day at 5.58. Company return on investment (ROI) is -69.70% and its monthly performance is recorded as 12.05%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) quarterly revenue growth is 11.16%.